
This video presentation of the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands features Dr. Stephan Weidinger, Dr. Eric Simpson, and Dr. Marjolein de Bruin-Weller. The faculty investigate the inflammatory processes driven by type 2 cytokines that lead to the local and systemic clinical effects of AD, the potential benefits of treating patients with AD early in the disease course, and the emerging real-world data on the use of advanced systemic therapies for patients with AD.
Listen to the latest updates in type 2 inflammatory science and associated skin diseases, brought to you by leading dermatology experts in the field. ADVENT On Air podcasts feature scientific conversations that explore new research into the pathophysiology, clinical features, and disease burden for a range of dermatological diseases linked to type 2 inflammation, including atopic dermatitis (AD) and prurigo nodularis (PN). Hear new insights revealed through expert-led conversations below or in your preferred podcast app.

An infographic to explore the the key roles of CCL17 (TARC) in atopic dermatitis.

Explore 3 hypothetical patient cases using guideline-based checklists for assessment and diagnosis of type 2 inflammation in adult asthma

This podcast episode discusses best practices for the diagnosis of atopic dermatitis of the hands and feet
Join Dr. Aceves and Ms. Ugras as they share their insights on how to identify potential patients with EoE and the importance of early diagnosis.
This video supports improved clinical awareness and encourages comprehensive care strategies for patients living with both CRSwNP and asthma.

In this video soundbite from the ERS-ISIAN 2025 symposium, Dr. Sietze Reitsma discusses findings from the EVEREST trial, the first head-to-head study comparison of dupilumab and omalizumab in patients with severe CRSwNP and coexisting asthma. It also introduces the ongoing TORNADO study.

Highlights from the ADVENT educational symposium at EADV 2024 discussing the current understanding of the science and treatment landscape in bullous pemphigoid (BP).
Dr. Elena Netchiporouk illustrates key considerations for diagnosing CSU at EADV 2025.

In this video of the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Perla Lansang reviews the current and emerging treatment options for children with AD uncontrolled with topical therapy, including a summary of recent long-term data for advanced systemic therapies

In this highlight video from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, Dr. Eric Simpson explores potential considerations when discussing the concept of disease modification and how early intervention might be disease modifying in AD.